The acquisition advances Revenio's growth strategy to improve ophthalmic diagnostics through innovative products. Thirona Retina will leverage AI technology for enhanced patient outcomes and care.
The integration of RetCAD technology into iCare's ILLUME and other retinal screening solutions enhances the early detection capabilities for eye diseases such as AMD and DR.
Jouni Toijala, CEO of Revenio Group, stated, 'AI will increasingly be integrated into a wide range of products. This acquisition bolsters our aim to develop more AI-based solutions for eye care.'
Thirona Retina’s future plans include continuing to sell RetCAD solutions in the market, allowing for broader engagement and use of their AI technology across the ophthalmology field.
[
Collection
]
[
|
...
]